


AMENDMENTS TO THE CLAIMS


Claims 1 to 28 (cancelled)

Claim 29 (currently amended)


A carbohydrate peptide conjugate comprising a dendrimeric poly-lysine carrier enabling multiple epitopes B and T to be covalently attached thereto, wherein said carbohydrate peptide conjugate is selected from the group consisting of the conjugates of the following formulae:




(B1-T4-M)



(B2-T2-M)



(B6-T8-M)



wherein:

- B denotes a structurally defined carbohydrate moiety which is a tumor antigen, or a derivative thereof, containing B epitope other than a sialoside, or several identical or different B epitopes;
- T denotes a peptide comprising one CD4<sup>+</sup> T epitope or several identical or different T-epitopes;
- K denotes a lysine ~~from 1 to 13~~ residue;
- n is an integer from 1 to 13;
- m is an integer from 1 to 9; and

wherein the B and T groups are covalently attached to the poly-lysine carrier.

**Claim 30** (previously presented)

A conjugate of claim 29 wherein the carbohydrate moiety is galactosyl.

**Claim 31** (currently amended)

A conjugate of claim 29 which comprises 3 lysine residues, at least 2 CD4<sup>+</sup> T cell epitopes, which may be the same or different, linked to the NH<sub>2</sub> ends of 2 of the lysine residues and 4  $\alpha$ -galactosyl-N-acetyl-Serine residues.

**Claim 32 (previously presented)**

A conjugate of claim 29 wherein the carbohydrate moiety is a galactosyl residue and is substituted with a glycosyl residue.

**Claims 33 – 34 (cancelled)**

**Claim 35 (cancelled)**

**Claims 36 – 37 (cancelled)**

**Claim 38 (previously presented)**

A conjugate of claim 29 wherein the carbohydrate is selected from the group consisting of Tn antigen, di-Tn antigen, Tri-Tn antigen, T<sup>\*</sup> antigen and hexa-Tn antigen.

**Claim 39 (previously presented)**

A pharmaceutical composition comprising the conjugate of claim 29 and a suitable carrier and adjuvant.

**Claim 40 (previously presented)**

A vaccine comprising the conjugate of claim 29.

**Claim 41 (cancelled)****Claim 42 (previously presented)**

An immunogenic composition comprising at least one carbohydrate peptide conjugate of claim 29 wherein said composition is capable of increasing the survival of a tumor bearing human or animal.

**Claim 43 (currently amended)**

An immunogenic composition comprising at least one carbohydrate conjugate of claim 42 wherein said conjugate comprises different carbohydrate antigens to induce more efficient anti-tumor immunity against cancers.

**Claim 44 (currently amended)**

A method of inducing an immune response to at least one member of the group consisting of B-cells and CD4<sup>+</sup> T-cells in a human or animal body, wherein the conjugate of claim 29 is administered to said human or animal body.

**Claims 45 (cancelled)****Claim 46 (cancelled)**

**Claim 47 (previously presented)**

A method of vaccination of a human or animal body wherein the conjugate of claim 29 is administered to said human or animal body.